QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:GLMD

Galmed Pharmaceuticals (GLMD) Stock Forecast, Price & News

$4.34
0.00 (0.00%)
(As of 04:18 PM ET)
Compare
Today's Range
$4.33
$4.45
50-Day Range
$4.30
$7.05
52-Week Range
$3.43
$14.18
Volume
6,739 shs
Average Volume
16,941 shs
Market Capitalization
$7.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GLMD stock logo

About Galmed Pharmaceuticals (NASDAQ:GLMD) Stock

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GLMD Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
Galmed Pharmaceuticals (GLMD) to Release Earnings on Friday
GLMD Galmed Pharmaceuticals Ltd.
See More Headlines

GLMD Price History

GLMD Company Calendar

Last Earnings
6/01/2023
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLMD
Employees
18
Year Founded
N/A

Profitability

Net Income
$-17,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.98 per share

Miscellaneous

Free Float
1,348,000
Market Cap
$7.31 million
Optionable
Optionable
Beta
1.11

Key Executives

  • Allen Baharaff
    Chairman, President & Chief Executive Officer
  • Guy Nehemya
    Chief Operating & Data Protection Officer
  • Doron Cohen
    Chief Financial Officer
  • Liat Hayardeny
    Chief Scientific Officer
  • Neta Tobis
    Director-Clinical Affairs













GLMD Stock - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View GLMD analyst ratings
or view top-rated stocks.

How have GLMD shares performed in 2023?

Galmed Pharmaceuticals' stock was trading at $7.50 at the start of the year. Since then, GLMD stock has decreased by 42.0% and is now trading at $4.35.
View the best growth stocks for 2023 here
.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 19,800 shares, an increase of 1,700.0% from the April 30th total of 1,100 shares. Based on an average daily volume of 23,100 shares, the short-interest ratio is currently 0.9 days. Currently, 1.4% of the company's shares are sold short.
View Galmed Pharmaceuticals' Short Interest
.

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our GLMD earnings forecast
.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings data on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.41.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals's stock reverse split on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (5.35%).

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $4.35.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $7.31 million. The biopharmaceutical company earns $-17,870,000.00 in net income (profit) each year or ($7.9866) on an earnings per share basis.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447.

This page (NASDAQ:GLMD) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -